

Contents

I Foundations in Drug Research

1	Drug Research: Yesterday, Today, and Tomorrow	3
1.1	It All Began with Traditional Medicines	5
1.2	Animal Experiments as a Starting Point for Drug Research	6
1.3	The Battle Against Infectious Disease	7
1.4	Biological Concepts in Drug Research	7
1.5	<i>In Vitro</i> Models and Molecular Test Systems	8
1.6	The Successful Therapy of Psychiatric Illness	9
1.7	Modeling and Computer-Aided Design	10
1.8	The Results of Drug Research and the Drug Market	11
1.9	A Subject of Conflict: Pharmaceuticals	12
1.10	Synopsis	13
	Bibliography and Further Reading	14
2	In the Beginning, There Was Serendipity	15
2.1	Acetanilide Instead of Naphthalene: A New, Valuable Antipyretic	16
2.2	Anesthetics and Sedatives: Pure Accidental Discovery	16
2.3	Fruitful Synergies: Dyes and Pharmaceuticals	17
2.4	Fungi Kill Bacteria and Help with Syntheses	18
2.5	The Discovery of the Hallucinogenic Effect of LSD	19
2.6	The Synthetic Route Determines the Structure	19
2.7	Surprising Rearrangements Lead to Medicines	20
2.8	A Long List of Accidents	21
2.9	Where Would We Be Without Serendipity?	21
2.10	Synopsis	22
	Bibliography and Further Reading	22
3	Classical Drug Research	23
3.1	Aspirin: A Never-Ending Story	24
3.2	Malaria: Success and Failure	26
3.3	Morphine Analogues: A Molecule Cut to Pieces	30
3.4	Cocaine: Drug and Valuable Lead Structure	32
3.5	H ₂ Antagonists: Ulcer Therapy Without Surgery	33
3.6	Synopsis	36
	Bibliography and Further Reading	37
4	Protein–Ligand Interactions as the Basis for Drug Action	39
4.1	The Lock-and-Key Principle	41
4.2	The Essential Role of the Membrane	42
4.3	The Binding Constant K_i Describes the Strength of Protein–Ligand Interactions	43
4.4	Important Types of Protein–Ligand Interactions	45
4.5	The Strength of Protein–Ligand Interactions	48
4.6	Blame It All on Water!	49
4.7	Thermodynamic Contributions to the Formation of Protein–Ligand Complexes	50
4.8	What Is the Contribution of a Hydrogen Bond to the Strength of Protein–Ligand Interactions?	52
4.9	The Strength of Hydrophobic Protein–Ligand Interactions	57
4.10	Binding and Mobility: Compensation of Enthalpy and Entropy	58
4.11	Lessons for Drug Design	62
4.12	Synopsis	63
	Bibliography and Further Reading	64

5	Optical Activity and Biological Effect	67
5.1	Louis Pasteur Sorts Crystals	68
5.2	Structural Basis of Optical Activity	69
5.3	The Isolation, Synthesis, and Biosynthesis of Enantiomers.....	71
5.4	Lipases Separate Racemates	72
5.5	Differences in the Activity of Enantiomers	74
5.6	Image and Mirror Image: Why Is It Different for the Receptor?.....	78
5.7	An Excursion into the World of Stereoisomers	80
5.8	Synopsis	81
	Bibliography and Further Reading.....	81
II	The Search for the Lead Structure	
6	The Classical Search for Lead Structures	85
6.1	How It Began: Hits by <i>In Vivo</i> Screening.....	86
6.2	Lead Structures from Plants	86
6.3	Lead Structures from Animal Venoms and Other Ingredients.....	87
6.4	Lead Structures from Microbial Organisms.....	88
6.5	Dyes and Intermediates Lead to New Drugs	89
6.6	Mimicry: How to Copy Endogenous Ligands	90
6.7	Side Effects Indicate New Therapeutic Options	91
6.8	From the Traditional Search to the Screening of Large Compound Libraries.....	92
6.9	Synopsis	93
	Bibliography and Further Reading.....	93
7	Screening Technologies for Lead Structure Discovery	95
7.1	Screening for Biological Activity by HTS	96
7.2	Color Change Demonstrates Activity.....	97
7.3	Getting Faster and Faster: More and More Compounds by Using Less and Less Material.....	97
7.4	From Binding to Function: Testing in Entire Cells.....	98
7.5	Back to Whole-Animal Models: Screening on Nematodes.....	99
7.6	<i>In Silico</i> Screening of Virtual Compound Libraries.....	100
7.7	Biophysics Supports Screening.....	102
7.8	Screening by Using Nuclear Magnetic Resonance.....	106
7.9	Crystallographic Screening for Small Molecular Fragments.....	108
7.10	Tethered Ligands Explore Protein Surfaces	109
7.11	Synopsis	112
	Bibliography and Further Reading.....	112
8	Optimization of Lead Structures	115
8.1	Strategies for Drug Optimization.....	116
8.2	Isosteric Replacement of Atoms and Functional Groups	117
8.3	Systematic Variation of Aromatic Substituents: The Topliss Trees	118
8.4	Optimizing the Activity and Selectivity Profile	118
8.5	From Agonists to Antagonists.....	119
8.6	Optimizing Bioavailability and Duration of Action	120
8.7	Variations of the Spatial Pharmacophore	121
8.8	Optimizing Affinity, Enthalpy, and Entropy of Binding and Binding Kinetics	122
8.9	Synopsis	125
	Bibliography and Further Reading.....	125

9	Designing Prodrugs	127
9.1	Foundations of Drug Metabolism	128
9.2	Esters Are Ideal Prodrugs	129
9.3	Chemically Well Wrapped: Multiple Prodrug Strategies	131
9.4	L-DOPA Therapy: A Clever Prodrug Concept	132
9.5	Drug Targeting, Trojan Horses, and Pro-prodrugs	133
9.6	Synopsis	135
	Bibliography and Further Reading	136
10	Peptidomimetics	137
10.1	Therapeutic Relevance of Peptides	138
10.2	Designing Peptidomimetics	139
10.3	First Step to Variation: Modifying Side Chains	140
10.4	A More Courageous Step: Modifying the Main Chain	140
10.5	Rigidifying the Backbone by Fixing Conformations	141
10.6	Peptidomimetics to Interfere with Protein–Protein Interactions	143
10.7	Tracing Selective NK Receptor Antagonists by Ala Scan	145
10.8	CAVEAT: Idea Generator for the Design of Peptidomimetics	147
10.9	Design of Peptidomimetics: <i>Quo Vadis?</i>	148
10.10	Synopsis	148
	Bibliography and Further Reading	149
III	Experimental and Theoretical Methods	
11	Combinatorics: Chemistry with Big Numbers	153
11.1	How Nature Produces Chemical Multiplicity	154
11.2	Protein Biosynthesis as a Tool to Build Compound Libraries	155
11.3	Organic Chemistry from a Different Angle: Random-Guided Synthesis of Compound Mixtures	155
11.4	What Is Contained in Chemical Space?	156
11.5	Compound Libraries on Solid Support: Complete Conversion and Easy Purification ..	157
11.6	Compound Libraries on Solid Support Need Sophisticated Synthetic Strategies	157
11.7	Which Compound in the Solid Support Combinatorial Library Is Biologically Active? ...	158
11.8	Combinatorial Libraries with Large Diversity: A Challenge for Synthetic Chemistry ...	159
11.9	Nanomolar Ligands for G-Protein-Coupled Receptors	160
11.10	More Potent than Captopril: A Hit from a Combinatorial Library of Substituted Pyrrolidines	161
11.11	Parallel or Combinatorial, in Solution or on a Solid Support?	161
11.12	The Protein Finds Its Own Optimal Ligand: Click Chemistry and Dynamic Combinatorial Chemistry	163
11.13	Synopsis	165
	Bibliography and Further Reading	166
12	Gene Technology in Drug Research	169
12.1	The History and Basics of Gene Technology	170
12.2	Gene Technology: A Key Technology in Drug Design	171
12.3	Genome Projects Decipher Biological Constructions	173
12.4	What Is Contained in the Biological Space of the Human Proteome?	174
12.5	Knock in, Knock out: Validation of Therapeutic Concepts	176
12.6	Recombinant Proteins for Molecular Test Systems	177
12.7	Silencing Genes by RNA Interference	178
12.8	PROTAC: How to force therapeutically untargetable proteins into targeted degradation	179
12.9	Proteomics and Metabolomics	180

12.10	Expression Patterns on a Chip: Microarray Technology	182
12.11	SNPs and Polymorphism: What Makes Us Different	183
12.12	The Personal Genome: Access to an Individualized Therapy?	184
12.13	When Genetic Differences Turn into Disease	184
12.14	Epigenetics: Lifestyle and Environment Influence Gene Activity Like a Pen Leaves a Mark in the Book of Life	185
12.15	The Scope and Limitations of Gene Therapy	187
12.16	Synopsis	189
	Bibliography and Further Reading	190
13	Experimental Methods of Structure Determination	193
13.1	Crystals: Aesthetic on the Outside, Periodic on the Inside	194
13.2	Just Like Wallpaper: Symmetries Govern Crystal Packings	196
13.3	Crystal Lattices Diffract X-Rays	196
13.4	Crystal Structure Analysis: Evaluating the Spatial Arrangement and Intensity of Diffraction Patterns	197
13.5	Diffraction Power and Resolution Determine the Accuracy of a Crystal Structure	201
13.6	Electron Microscopy: Topographic Images Reveal Macromolecular Structures	205
13.7	Structures in Solution: The Resonance Experiment in NMR Spectroscopy	208
13.8	From Spectra to Structure: Distance Maps Evolve into Spatial Geometries	209
13.9	How Relevant Are Structures in a Crystal or NMR Tube to a Biological System?	211
13.10	Synopsis	212
	Bibliography and Further Reading	213
14	Three-Dimensional Structure of Biomolecules	215
14.1	The Amide Bond: Backbone of Proteins	216
14.2	Proteins Fold in Space to Form α-Helices and β-Strands	217
14.3	From Secondary Structure Via Motifs and Domains to Tertiary and Quaternary Structure	220
14.4	Are the Fold Structure and Biological Function of Proteins Correlated?	223
14.5	Proteases Recognize and Cleave Substrates in Well-Tailored Pockets	224
14.6	From Substrate to Inhibitor: Screening of Substrate Libraries	224
14.7	When Crystal Structures Learn to Move: From Static Structures to Dynamics and Reactivity	226
14.8	Solutions to the Same Problem: Serine Proteases with Differing Folds Have Identical Function	227
14.9	DNA as a Target Structure of Drugs	228
14.10	Synopsis	230
	Bibliography and further reading	231
15	Molecular Modeling	233
15.1	3D Structural Models as Well-Established Tools in Chemistry	234
15.2	Strategies in Molecular Modeling	234
15.3	Knowledge-Based Approaches	235
15.4	Force Field Methods	236
15.5	Quantum Chemical Methods	237
15.6	Computing and Analyzing Molecular Properties	239
15.7	Molecular Dynamics: Simulation of Molecular Motion	239
15.8	Dynamics of a Flexible Protein in Water	242
15.9	Model and Simulation: Where Are the Differences?	243
15.10	Synopsis	244
	Bibliography and further reading	245

16	Conformational Analysis	247
16.1	Many Rotatable Bonds Create Large Conformational Multiplicity	248
16.2	Conformations Are the Local Energy Minima of a Molecule	249
16.3	How to Scan Conformational Space Efficiently?	249
16.4	Is It Necessary to Search the Entire Conformational Space?	250
16.5	The Difficulty in Finding Local Minima Corresponding to the Receptor-Bound State...	251
16.6	An Effective Search for Relevant Conformations by Using a Knowledge-Based Approach	252
16.7	What Is the Outcome of a Conformational Search?	253
16.8	Synopsis	253
	Bibliography and Further Reading	253
IV	Quantitative Structure-Activity Relationships and Design Approaches	
17	Pharmacophore Hypotheses and Molecular Comparisons	257
17.1	The Pharmacophore Anchors a Drug Molecule in the Binding Pocket	258
17.2	Structural Superposition of Drug Molecules	258
17.3	Logical Operations with Molecular Volumes	259
17.4	The Pharmacophore is Modified by Conformational Transitions	260
17.5	Systematic Conformational Search and Pharmacophore Hypothesis: The “Active Analog Approach”	262
17.6	Molecular Recognition Properties and the Similarity of Molecules	263
17.7	Automated Molecular Comparisons and Superpositioning Based on Recognition Properties	264
17.8	Rigid Analogues Trace the Biologically Active Conformation	266
17.9	If Rigid Analogues are Lacking: Model Compounds Elucidate the Active Conformation.	266
17.10	The Protein Defines the Pharmacophore: “Hot Spot” Analysis of the Binding Pocket ...	267
17.11	Searching for Pharmacophore Patterns in Databases Generates Ideas for Novel Lead Compounds	270
17.12	Synopsis	271
	Bibliography and Further Reading	272
18	Quantitative Structure–Activity Relationships	273
18.1	How It All Began: Structure–Activity Relationships of Alkaloids	274
18.2	From Richet, Meyer, and Overton to Hammett and Hansch	274
18.3	The Determination and Calculation of Lipophilicity	275
18.4	Lipophilicity and Biological Activity	275
18.5	The Hansch Analysis and the Free–Wilson Model	276
18.6	Structure–Activity Relationships of Molecules in Space	278
18.7	Structural Alignment as a Prerequisite for the Relative Comparison of Molecules	278
18.8	Binding Affinities as Compound Properties	278
18.9	How Is a CoMFA Analysis Performed?	279
18.10	Molecular Fields as Criteria of a Comparative Analysis	280
18.11	3D-QSAR: Correlation of Molecular Fields with Biological Properties	280
18.12	Results of a Comparative Molecular Field Analysis and Their Graphical Interpretation	282
18.13	Scope, Limitations, and Possible Expansions of the CoMFA Analysis	283
18.14	A Glimpse Behind the Scenes: Comparative Molecular Field Analysis of Carbonic Anhydrase Inhibitors	284
18.15	Synopsis	287

	Bibliography and Further Reading	288
19	From In Vitro to In Vivo: Optimization of ADME and Toxicology Properties ..	291
19.1	Rate Constants of Compound Transport	292
19.2	Absorption of Organic Molecules: Model and Experimental Data.....	294
19.3	The Role of Hydrogen Bonds	294
19.4	Distribution Equilibria of Acids and Bases.....	295
19.5	Absorption Profiles of Acids and Bases.....	296
19.6	What Is the Optimal Lipophilicity of a Drug?	298
19.7	Computer Models and Rules to Predict ADME Parameters.....	299
19.8	From <i>In Vitro</i> to <i>In Vivo</i> Activity	300
19.9	Compartmentalization: Natural Ligands Are Often Unspecific.....	300
19.10	Specificity and Selectivity of Drug Interactions	301
19.11	Of Mice and Men: The Value of Animal Models.....	302
19.12	Toxicity and Adverse Effects.....	304
19.13	Animal Protection and Alternative Test Models	306
19.14	Synopsis	306
	Bibliography and Further Reading	308
20	Protein Modeling and Structure-Based Drug Design	309
20.1	Pioneering Studies in Structure-Based Drug Design	310
20.2	Strategies in Structure-Based Drug Design	311
20.3	Search Tools for Databases of Experimentally Determined Protein Complexes.....	312
20.4	Comparison of Protein-Binding Pockets.....	312
20.5	High Sequence Identity Facilitates Model Generation	312
20.6	Secondary Structure Prediction and Amino Acid Replacement Propensities Support Model Building at Low Sequence Identity.....	314
20.7	Ligand Design: Seeding, Expanding, and Linking	316
20.8	Docking Ligands into Binding Pockets	316
20.9	Scoring Functions: Ranking of Constructed Binding Geometries	318
20.10	<i>De Novo</i> Design: From LUDI to the Automated Assembly of Novel Ligands.....	318
20.11	The Feasibility of Designing Ligands <i>In Silico</i>	319
20.12	Synopsis	320
	Bibliography and Further Reading.....	320
21	A Case Study: Structure-Based Inhibitor Design for tRNA-Guanine Transglycosylase.....	323
21.1	Shigellosis: Disease and Therapeutic Options.....	325
21.2	Blocking Pathogenesis on the Molecular Level.....	325
21.3	The Crystal Structure of tRNA-Guanine Transglycosylase as a Starting Point	326
21.4	A Functional Assay to Determine Binding Constants.....	326
21.5	LUDI Discovers the First Leads.....	329
21.6	Surprise: A Flipped Amide Bond and a Water Molecule	330
21.7	Hot Spot Analysis and Virtual Screening Open the Floodgate to New Ideas for Synthesis.....	331
21.8	The Filling of Hydrophobic Pockets and Interference with a Water Network.....	332
21.9	With a Salt Bridge: Finally Nanomolar!	334
21.10	Surprise: The Enzyme is Only Functional as a Dimer	338
21.11	Site-directed Mutagenesis: What Binds the Dimer Together	340
21.12	When Nothing Else Works: Chemical Poking at the Contact Interface.....	342
21.13	Only Serendipity Can Help: Different Crystal Form—New Dimer	343
21.14	Tracking the Dynamic Transformation with the Appropriate Spins	343
21.15	When Sulfur Accidentally Oxidizes and Starts a Fragment Design Project in a New Arrangement	346
21.16	A Fragment Opens a Transient Pocket and Suggests the Design of Bacteria-specific Inhibitors	349
21.17	Many Ways to a Smart Antibiotic Against Shigellosis	350

21.18	Synopsis	352
	Bibliography and Original Papers.....	353
V	Drugs and Drug Action: Successes of Structure-Based Design	
22	How Drugs Act: Concepts for Therapy	357
22.1	The Druggable Genome	358
22.2	Enzymes as Catalysts in Cellular Metabolism	359
22.3	How Do Enzymes Push Substrates Towards the Transition State?	360
22.4	Enzymes and Their Inhibitors	361
22.5	Receptors as Target Structures for Drugs	362
22.6	Drugs Regulate Ion Channels: Our Extremely Fast Switches	364
22.7	Blocking Transporters and Water Channels	364
22.8	Modes of Action: A Never-Ending Story	365
22.9	Resistance and Its Origin	367
22.10	Combined Administration of Drugs	368
22.11	Synopsis	368
	Bibliography and Further Reading.....	369
23	Inhibitors of Hydrolases with an Acyl–Enzyme Intermediate	371
23.1	Serine-Dependent Hydrolases	372
23.2	Structure and Function of Serine Proteases	372
23.3	The S₁ Pocket of Serine Proteases Determines Specificity	374
23.4	Seeking Small-Molecule Thrombin Inhibitors	376
23.5	Design of Orally Available Low Molecular Weight Elastase Inhibitors	384
23.6	Serine Protease Inhibitors: Thrombin Was Just the Starting Point	385
23.7	Serine, a Favored Nucleophile in Degrading Enzymes	390
23.8	Triads in All Variations: Threonine as a Nucleophile	394
23.9	Cysteine Proteases: Sulfur, the Big Brother of Oxygen as a Nucleophile in the Triad ...	396
23.10	Synopsis	400
	Bibliography and Further Reading.....	400
24	Aspartic Protease Inhibitors	403
24.1	Structure and Function of Aspartic Proteases	404
24.2	Design of Renin Inhibitors	405
24.3	Design of Substrate Analogue HIV Protease Inhibitors	411
24.4	Structure-Based Design of Nonpeptidic HIV Protease Inhibitors	413
24.5	The Development of Resistance Against HIV Protease Inhibitors	416
24.6	A Basic Nitrogen as a Partner for the Aspartic Acids of the Catalytic Dyad	418
24.7	Other Targets from the Family of Aspartic Proteases	423
24.8	Synopsis	423
	Bibliography and Further Reading.....	424
25	Inhibitors of Hydrolyzing Metalloenzymes	427
25.1	Structure of Zinc Metalloproteases	428
25.2	Key Step in the Design of Metalloprotease Inhibitors: Binding to the Zinc Ion	429
25.3	Thermolysin: Tailored Design of Enzyme Inhibitors	431
25.4	Captopril, a Metalloprotease Inhibitor for Hypertension Therapy	432
25.5	Finally the Crystal Structure of ACE: Does a Success Story Have to Be Rewritten?	434
25.6	Inhibitors of Matrix Metalloproteases: An Approach to Treat Cancer and Rheumatoid Arthritis?	436
25.7	Carbonic Anhydrases: Catalysts of a Simple but Essential Reaction	440
25.8	A Case for Two: Zinc and Magnesium in the Catalytic Centers of Phosphodiesterases ..	444
25.9	What Zinc Can Do, Iron Can Too	446

25.10	Acetyl Group Cleavage Condenses Chromatin and Regulates Reading of Gene Segments: An Opportunity for Therapy?	447
25.11	Synopsis	449
	Bibliography and Further Reading	450
26	Transferase Inhibitors	451
26.1	The Kinase “Gold Rush”	452
26.2	Structure of Protein Kinases: More than 500 Variations with Similar Geometry	453
26.3	Isosteric with ATP, and Selective Nonetheless?	454
26.4	Gleevec[®]: Success Stories Breed Copycats!	458
26.5	Tracing Selectivity: The Bump-and-Hole Method	462
26.6	Metals Teach Kinase Inhibitors Selectivity	464
26.7	Phosphatases: Reversal Switch to Activate and Inactivate Proteins	466
26.8	Inhibitors of PTP-1B: Treatment for Diabetes and Obesity?	468
26.9	Molecular Glue Inhibits the Release of Phosphatase Activity	472
26.10	Inhibitors of Catechol-O-Methyltransferase	473
26.11	Blocking the Transfer of Farnesyl and Geranyl Anchors	477
26.12	Synopsis	480
	Bibliography and Further Reading	481
27	Oxidoreductase Inhibitors	483
27.1	Redox Reactions in Biological Systems Use Cofactors	484
27.2	Chemotherapeutics for Cancer and Bacteria: Dihydrofolate Reductase Inhibitors	487
27.3	HMG-CoA Reductase Inhibitors: The Changing Fate of Drug Development	490
27.4	Hitting a Moving Target: Aldose Reductase Inhibitors	496
27.5	11β-Hydroxysteroid Dehydrogenase	500
27.6	The Cytochrome P450 Enzyme Family	502
27.7	What Makes Slow and Fast Metabolizers Different?	506
27.8	Blocking the Degradation of Neurotransmitters: Monoamine Oxidase Inhibitors	508
27.9	Cyclooxygenase: A Key Enzyme in Pain Sensation	512
27.10	Synopsis	518
	Bibliography and Further Reading	519
28	Agonists and Antagonists of Nuclear Receptors	521
28.1	Nuclear Receptors Are Transcription Factors	522
28.2	The Structure of Nuclear Receptors	523
28.3	Steroid Hormones: How Small Differences Translate to the Receptor	523
28.4	Helix Open, Helix Closed: How Agonists and Antagonists Are Differentiated	525
28.5	Agonists and Antagonists of Steroid Hormone Receptors	527
28.6	Ligands of PPAR Receptors	531
28.7	Ligands of Nuclear Receptors Stimulate Metabolism	533
28.8	Synopsis	535
	Bibliography and Further Reading	536
29	Agonists and Antagonists of Membrane-Bound Receptors	537
29.1	The Family of G-Protein-Coupled Receptors	538
29.2	Rhodopsins Provide the First Models of G-Protein-Coupled Receptors	540
29.3	Structure of the Human β_2-Adrenergic Receptor	541
29.4	How Does a GPCR Communicate with Its Macromolecular Protein Partners in the Cell?	544
29.5	Peptide-Binding Receptors: Development of Angiotensin II Antagonists	547
29.6	Do Peptidic Agonists and Small-Molecule Antagonists Bind at the Same Position of the AT₁ Receptor?	548

29.7	Lessons Taught by the Nose: We Smell with GPCRs.....	551
29.8	Receptor Tyrosine Kinases and Cytokine Receptors: Where Insulin, EPO, and Cytokines Display Their Activity	552
29.9	Synopsis	557
	Bibliography and Further Reading.....	559
30	Ligands for Channels, Pores, and Transporters	561
30.1	Electric Potential and Ion Gradients Stimulate Cells.....	562
30.2	Molecular Function of a Potassium Channel at the Atomic Level	564
30.3	Binding Undesirable: The hERG Potassium Channel as an Antitarget.....	567
30.4	Electromechanical Control of Voltage-Dependent Ion Channels: How Small Ligands Tighten or Loosen a Hydrophobic Belt in Ion Channels	569
30.5	Tiny Ligands Gate Giant Ion Channels.....	574
30.6	Ligands Gate as Agonists and Antagonists: The Function of an Ion Channel.....	576
30.7	Power Brake Boosters for GABA-Gated Chloride Channels.....	579
30.8	The Mode of Action of a Voltage-Gated Chloride Channel	585
30.9	ATP Hydrolysis Fuels Ion Flux Against Concentration Gradients	586
30.10	Transporters: The Gatekeepers to the Cell.....	587
30.11	Membrane Passage in Bacteria: Pores, Carriers, and Channel Formers.....	590
30.12	Aquaporins Regulate the Cellular Water Inventory.....	591
30.13	Synopsis	592
	Bibliography and Further Reading.....	594
31	Ligands for Surface Receptors	597
31.1	The Family of Integrin Receptors	598
31.2	Successful Design of Peptidomimetic Fibrinogen Receptor Antagonists	600
31.3	Selectins: Surface Receptors Recognizing Carbohydrates.....	603
31.4	Fusion Inhibitors Impede Viral Invasion	605
31.5	Neuraminidase Inhibitors Prevent Budding of Mature Viruses.....	607
31.6	Stopping the Common Cold: Inhibitors for the Capsid Protein of Rhinovirus.....	612
31.7	MHC Molecules: Where the Immune System Presents Peptide Fragments	616
31.8	Synopsis	622
	Bibliography and Further Reading.....	623
32	Biologicals: Peptides, Proteins, Nucleotides, and Macrolides as Drugs	625
32.1	Gene-Technological Production of Proteins.....	626
32.2	Tailored Modifications to Insulin	627
32.3	Monoclonal Antibodies as Vaccines, Chemotherapeutics, and Receptor Antagonists ..	628
32.4	Antisense Oligonucleotides and mRNA as Drugs?	633
32.5	Nucleosides and Nucleotides as False Substrates	636
32.6	Molecular Wedges Destroy Protein–Nucleotide Recognition	639
32.7	Macrolides: Microbial Warheads as Potential Cytostatics, Antimycotics, Immunosuppressants, or Antibiotics.....	643
32.8	Synopsis	651
	Bibliography and Further Reading.....	652
	Service Part	
	Illustration Source References	656
	Name Index	663
	Subject Index	667